Home Ark versus Sark ARK VS. SARK | PAST STANCES Ark versus Sark ARK VS. SARK | PAST STANCES By Editor / Curator - October 4, 2022 Facebook Twitter Google+ Pinterest Linkedin Email Long SARK 3-13-2023 | $44.21 Long Ark Innovation 10-3-2022 | $37.90 #ARK, #ARKK, #SARK RELATED ARTICLESMORE FROM AUTHOR All News Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF. All News The Retreat of the Amateur Investors (WSJ) Ark versus Sark ARK vs. SARK Latest article Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX. Institutional Analyst Newsletter Editor / Curator - May 2, 2024 DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26... Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List. 2024 Watch List Editor / Curator - April 29, 2024 Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever! Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet. 2024 Watch List Editor / Curator - April 27, 2024 CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...